- Home
- ACHV vs NXP Comparison
ACHV vs NXP Comparison
Compare ACHV & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACHV | NXP |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 833.5M | 898.0M |
| IPO Year | 2018 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ACHV | NXP |
|---|---|---|
| Price | $8.48 | $14.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $14.67 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 138.7K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.62 | $13.89 |
| 52 Week High | $8.61 | $14.65 |
Technical Indicators
Market Signals| Indicator | ACHV | NXP |
|---|---|---|
| Relative Strength Index (RSI) | 69.38 | 39.06 |
| Support Level | $3.99 | $14.05 |
| Resistance Level | $8.61 | $14.49 |
| Average True Range (ATR) | 0.40 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 90.41 | 0.00 |
Price Performance
Historical ComparisonAbout ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund has single operating segment.